Navigation Links
Signum Biosciences, Inc. Announces Commercial Launch of Arazine™
Date:7/12/2010

PRINCETON, N.J., July 12 /PRNewswire/ -- Signum Biosciences announced that its partner, Rohto Pharmaceutical Co., Ltd., has launched AFC Medirepair® with Signum's compound Arazine™ (n-acetyl-s-farnsylcysteine or AFC) in Japan.  Arazine™ is the first compound from Signum's novel anti-inflammatory platform to be commercialized from Signum's pipeline of Signal Transduction Modulators (STMs). The DRx AFC Medirepair® website can be found at: http://www.drx-web.com/aa/prod_afc.htm .

"We're excited to launch Arazine™ in the Japanese market providing a completely new and effective product for treating skin inflammation," said Signum president, Maxwell Stock.  "The commercialization of Arazine™ is a significant milestone for Signum and validates our underlying business model."

Arazine™ is a Signal Transduction Modulator (STM) with anti-inflammatory properties, which has been developed for topical skin treatment.  STMs block inflammation and neutrophil infiltration in chronic redness, acne, skin irritation, and other skin conditions by modulating G-protein signal transduction pathways.  They also act as antioxidants to neutralize free radicals and prevent UV damage, cellular degeneration and production of chemicals that cause further damage.  Arazine™ is closely followed by Signum's pipeline of compounds including SIG990 which is being developed for rosacea and other inflammatory skin conditions.

Signum and Rohto announced their strategic alliance to develop and commercialize skincare products in Japan during 2008.  Rohto gained semi-exclusive rights to develop and sell products in Japan that contain Signum's anti-inflammatory compound Arazine™.  

About Signum Biosciences.

Signum Biosciences is a private biotechnology company dedicated to developing small-molecule therapeutics derived from its Signal Transduction Modulation (STM) platform to modulate signal transduction imbalances. Through research on protein networks that control biological systems, Signum is developing therapeutic candidates for Alzheimer's, Parkinson's, diabetes, asthma and certain skin conditions. Signum's STM technology provides many opportunities for the development of novel consumer products and pharmaceutical candidates.

For more information please visit the Signum website: www.signumbiosciences.com

About Rohto Pharmaceutical Co., Ltd.

Rohto Pharmaceutical Co., Ltd. is among the largest manufacturers and marketers of pharmaceutical and other healthcare products in Japan. Founded in 1899, the company is based in Osaka, Japan. Production sites include facilities in the U.S., Europe, Latin America, China and Southeast Asia with product distribution to over 150 countries including all of Asia, the Americas and Europe. In 1988 the company acquired management rights to prominent U.S. manufacturer, The Mentholatum Company, Inc. Corporate sales revenue in the latest fiscal year exceeded US$ 1 Billion. The Chairman and CEO is Mr. Kunio Yamada.

For more information please visit the Rohto website: www.rohto.co.jp/global


'/>"/>
SOURCE Signum Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
2. Ampio Pharmaceuticals to Acquire DMI Biosciences, Inc.
3. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
4. Neurocrine Biosciences, Inc. Prices Common Stock Offering
5. Hollis-Eden Announces Name Change to Harbor BioSciences, Inc. and Ticker Symbol Change to HRBR
6. Pressure BioSciences, Inc. Announces $850,000 NIH SBIR Phase II Award for the Development of a New PCT-dependent System for Improved Biomarker Discovery, Diagnostics, and Drug Discovery
7. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
8. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
9. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
10. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
11. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... N.J. , June 24, 2016  Collagen ... the design, development and manufacturing of collagen and ... regeneration announced today that Bill Messer ... and Marketing to further leverage the growing portfolio ... medical devices. Bill joins the Collagen ...
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their ... Award, an essay contest in which patients and their families pay tribute to a ... the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Grove Investment Group (TGIG), has initiated cultivation and processing operations at its production ... and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of ...
(Date:6/24/2016)... Washington, D.C. (PRWEB) , ... June 24, 2016 , ... ... Pro-Am Heroes Golf Classic Tournament held on June 20th at the Woodmont Country ... local charity, Luke’s Wings, an organization dedicated to helping service members that have been ...
Breaking Medicine News(10 mins):